免疫疗法
嵌合抗原受体
淋巴瘤
医学
封锁
免疫学
免疫系统
霍奇金淋巴瘤
免疫检查点
抗原
内科学
受体
作者
Reid W. Merryman,Roch Houot,Philippe Armand,Caron A. Jacobson
出处
期刊:The cancer journal
[Ovid Technologies (Wolters Kluwer)]
日期:2020-05-01
卷期号:26 (3): 269-277
被引量:4
标识
DOI:10.1097/ppo.0000000000000445
摘要
Abstract The promise of immunotherapy has shone brightly for decades in hematologic malignancies and specifically in non-Hodgkin lymphoma. The last decade has witnessed the emergence of completely novel forms of immunotherapy, including immune checkpoint blockade, bispecific antibodies, and chimeric antigen receptor T cells. These treatments have shown phenomenal, and in some cases possibly curative, successes in various relapsed/refractory lymphomas. This review summarizes the most notable successes and promising findings as well as some of the attendant failures. These treatments will doubtlessly transform the treatment paradigms across many lymphoma subtypes. Yet, only if we can better understand their mechanisms of action, toxicity, and resistance will be able to maximize their therapeutic benefit.
科研通智能强力驱动
Strongly Powered by AbleSci AI